Welcome to the Cell Culture World Congress USA

A technical conference for Scientists, Principal Investigators, Managers and Engineers 

 

SPONSOR NOW   REGISTER NOW

 

4 Events, 1 Location 

 

 

 

 

 

 

 

Cell Culture World USA is your best opportunity to get your name at the front of the minds of your target market. Make sure you’re there sponsoring or exhibiting to grab the attention of the brands you need to meet.
 

SPONSORSHIP PROSPECTUS


 

 

 

Optimizing upstream cell culture – a $25M market by 2018

Upstream cell culture is the single, most critical process in developing safe and efficacious biologics and vaccines; the therapies of the future for unmet medical needs. Yet it is volatile as it is expensive since it depends on living material for cure. 

This 4th annual Cell Culture World Congress USA is part of Terrapinn’s cell culture global series that brings together Heads, Principal Investigators, Scientists and Engineers from biopharmaceutical companies’ upstream cell culture divisions, to share and learn from each other novel and innovative strategies to streamline and manage cell culture processes better. 

 

Cell Culture World Congress USA

Cell Culture World Congress USA

Cell Culture World Congress USA

Cell Culture World Congress USA

Cell Culture World Congress USA

Previous sponsors include:

We have a proud track record in the upstream cell culture space, with an established presence in the US, Europe and Asia. This event is the event where you can find out what’s new, how it’s done and who is doing it in 2015. This is just a sample of who has joined us at our events in the past. 

Cell Culture World Congress USA

Cell Culture World Congress USA

Cell Culture World Congress USA

Cell Culture World Congress USA

Cell Culture World Congress USA

Cell Culture World Congress USA

Cell Culture World Congress USA

Cell Culture World Congress USA

Cell Culture World Congress USA

SPONSORSHIP PROSPECTUS

 

Exhibition booths are going quickly...

Choose your booth now!

 

 

 
New Benefit- Risk, PSUR, Benefit-Risk Assessment, drug safety

New Benefit-Risk PSUR: Impact on Benefit-Risk Assessment

At the 2014 World Drug Safety Congress Americas, Anne Wolka, Eli Lilly and Company, gave a presentation on “New Benefit-Risk PSUR: Impact on Benefit-Risk Assessment”. Download and learn: The rebirth of the PSUR Objective of the PBRER Critical Analysis of Benefits Critical Analysis of Risks Integrated Benefit-Risk Analysis Impact of the PBRER So What Is a […]

The post New Benefit-Risk PSUR: Impact on Benefit-Risk Assessment appeared first on Total Biopharma.

top-50-pharmaceutical-companies-20130

Top 50 Pharmaceutical Companies 2014

The Pharmaceutical and Biotechnology continue to dominate the world’s R&D expenditure, with more companies in the top 10 than any other sector. This year, whilst Novartis has knocked Roche from their top spot, individual R&D spends by pharma and biotechs fail to compete with the likes of Volkswagen and Samsung who’s spends were around $11 […]

The post Top 50 Pharmaceutical Companies 2014 appeared first on Total Biopharma.

Asian biotechs to look beyond Asia for growth

Earlier this year at BioPharma Asia Convention, when we spoke to some speakers about their thoughts on the key growth strategy that Asian biotech companies should adopt, there seemed to be a unanimous agreement that looking beyond Asia is the way to go. “Biotech companies in Asia have to think globally, and link globally. “ […]

The post Asian biotechs to look beyond Asia for growth appeared first on Total Biopharma.

Join the Community

Innovation and strategy for pharmaceutical, biotech and R&D

Sign Up to Our Newsletter